After the black box warning: Predictors of psychotropic treatment choices for older patients with dementia

Psychiatric Services

Volumn 62, Issue 10, 2011, Pages 1207-1214

  Kim, Hyungjin Myra ^a   Chiang, Claire ^a,b   Kales, Helen C ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROATE SEMISODIUM; VALPROIC ACID;

AGED; ANXIETY DISORDER; ARTICLE; DEMENTIA; DISEASE ASSOCIATION; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MORTALITY; NEUROPSYCHIATRY; PARKINSON DISEASE; RETROSPECTIVE STUDY;

EID: 80054864992     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/ps.62.10.pss6210_1207     Document Type: Article

References (21)

1. Public Health Advisory: Deaths With Antipsychotics in Elderly Patients With Behavioral Disturbances. Washington, DC, US Food and Drug Administration, Apr 11, 2005. Available at www.fda.gov/Drugs/ DrugSafety/ PostmarketDrugSafetyInforma tionforPatientsandProviders/DrugSafetyIn formationforHeathcareProfessionals/Public HealthAdvisories/ucm053171.htm
2. Schneider LS, Dagerman KS, Insel P: Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294:1934-1943, 2005 (Pubitemid 41464695)
3. Wang PS, Schneeweiss S, Avorn J, et al.: Risk of death in elderly users of conventional versus other psychiatric medications. New England Journal of Medicine 353:2335-2341, 2005 (Pubitemid 41713745)
4. Gill SS, Bronskill SE, Normand SL, et al.: Antipsychotic drug use and mortality in older adults with dementia. Annals of Internal Medicine 146:775-786, 2007 (Pubitemid 351650498)
5. Schneeweiss S, Setoguchi S, Brookhart A, et al.: Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. Canadian Medical Association Journal 176:627-632, 2007 (Pubitemid 46426056)
6. Kales HC, Valenstein M, Kim HM, et al.: Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. American Journal of Psychiatry 164:1568-1576, 2007 (Pubitemid 350069737)
7. Kales HC, Zivin K, Kim HM, et al.: Trends in antipsychotic use in dementia 1999-2007. Archives of General Psychiatry 68: 190-197, 2011
8. Charlson ME, Pompei P, Ales KL, et al.: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases 40:373-383, 1987 (Pubitemid 17055592)
9. Long SJ, Freese J: Regression Models for Categorical Dependent Variables Using Stata, 2nd ed. College Station, Tex, Stata Press, 2006
10. White H: A Heteroskedasticity-Consistent Covariance Matrix Estimator and a Direct Test for Heteroskedasticity. Econometrica 48:817-838, 1980
11. Copeland LA, Zeber JE, Valenstein M, et al.: Racial disparity in the use of atypical antipsychotic medications among veterans. American Journal of Psychiatry 160:1817-1822, 2003 (Pubitemid 41103316)
12. Valenti AM, Narendran R, Pristach CA: Who are patients on conventional antipsychotics? Schizophrenia Bulletin 29:195-199, 2003 (Pubitemid 37187684)
13. Cooper-Patrick L, Gallo JJ, Powe NR, et al.: Mental health service utilization by African Americans and Whites: the Baltimore Epidemiologic Catchment Area Follow- Up. Medical Care 37:1034-1045, 1999
14. Pingitore D, Snowden L, Sansone RA, et al.: Persons with depressive symptoms and the treatments they receive: a comparison of primary care physicians and psychiatrists. International Journal of Psychiatry in Medicine 31:41-60, 2001 (Pubitemid 32768590)
15. Schneider LS, Dagerman K, Insel PS: Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. American Journal of Geriatric Psychiatry 14:191-210, 2006
16. Lonergan E, Britton AM, Luxenberg J: Antipsychotics for delirium. Cochrane Database of Systematic Reviews 2:CD00 5594, 2007
17. Meltzer HY, Bobo WV: Interpreting the efficacy findings in the CATIE study: what clinicians should know. CNS Spectrums 11(suppl 7):14-24, 2006 (Pubitemid 44141225)
18. Fernandez HH, Triesxhmann ME, Friedman JH: Treatment of psychosis in Parkinson's disease: safety considerations. Drug Safety 26:643-649, 2003
19. Weintraub D, Chen P, Ignacio RV, et al.: Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. Archives of Neurology 68:899-904, 2011
20. Okura T, Plassman BL, Steffens DS, et al.: Prevalence of neuropsychiatric symptoms and their association with functional limitations in older adults in the United States: the Aging, Demographics and Memory Study. Journal of the American Geriatrics Society 58:330-337, 2010
21. Steffens DC, Fisher GG, Langa KM, et al.: Prevalence of depression among older Americans: the Aging, Demographics and Memory Study. International Psychogeriatrics 21:879-888, 2009